Chimeric Therapeutics (ASX:CHM) YoY EPS Growth: -61.22% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Chimeric Therapeutics YoY EPS Growth?

Chimeric Therapeutics ASX:CHM -14.29% YoY EPS Growth is -61.22% as of Jun. 2026. The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Chimeric Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 was -61.22%.

Chimeric Therapeutics's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was A$-0.61.

Chimeric Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics YoY EPS Growth Chart

Chimeric Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EPS Growth
Get a 7-Day Free Trial 44.85 -35.43 69.89 54.99 21.02

Chimeric Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.12 -164.85 76.90 -27.17 -61.22

Chimeric Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Chimeric Therapeutics's YoY EPS Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EPS Growth (A: Jun. 2026 )
=(Earnings per Share (Diluted) (A: Jun. 2026 )-Earnings per Share (Diluted) (A: Jun. 2025 ))/ | Earnings per Share (Diluted) (A: Jun. 2025 ) |
=(-0.6097--0.772)/ | -0.772 |
=21.02 %

Chimeric Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.6062--0.376)/ | -0.376 |
=-61.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -61.22% mean?
Chimeric Therapeutics (ASX:CHM) has a YoY EPS Growth of -61.22% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' YoY EPS Growth too high?
Chimeric Therapeutics' current YoY EPS Growth is -61.22%.
How does Chimeric Therapeutics' YoY EPS Growth compare to VRTX and REGN?
Chimeric Therapeutics' YoY EPS Growth of -61.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current YoY EPS Growth is -61.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (ASX:CHM) has a current YoY EPS Growth of -61.22%. The current YoY EPS Growth is -61.22%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Chimeric Therapeutics (ASX:CHM), the current YoY EPS Growth is -61.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.